© 1988 British Society for Rheumatology
research-article |
THE ONCOGENICITY OF CHLORAMBUCIL IN RHEUMATOID ARTHRITIS
1Department of Rheumatology,Si. Vincent's Hospital Darlinghursl, 2010,Australia
2Garvan Institute of Medical Research,Si. Vincent's Hospital Darlinghursl, 2010, Australia
3Department of Clinical Pharmacology, Si. Vincent's Hospital Darlinghursl, 2010,Australia
Correspondence to:
Address correspondence to Dr. P. Sambrook.
Chlorambucil is useful in patients with rheumatoid arthritis (RA) refractory to other agents but there is concern about the risk of haematological malignancy with this agent. A retrospective survey was performed to assess the incidence of all types of malignancy in 39 patients treated with chlorambucil (mean daily dose 4.25 mg, mean duration of treatment 25 months). These patients were compared with 30 patients with RA who received contemporaneously, the purine analogues azathioprine or 6-mercap-topurine (mean dose 100 mg, mean duration of treatment 24 months). Eight patients treated with chlorambucil and one patient receiving purine analogues developed cutaneous malignancy (p = 0.03). In the chlorambucil-treated patients these were mostly multiple and recurrent. Three patients treated with chlorambucil developed myeloid leukaemia or a preleukaemic state, whilst no patient treated with purine analogues developed this complication. The use of chlorambucil in RA is associated with an increased risk of cutaneous as well as haematological oncogenesis.
KEY WORDS: Rheumatoid arthritis, Chlorambucil, Leukaemia, Cutaneous malignancy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. D. Summers, C. M. Deighton, M. J. Rennie, and A. H. Booth Rheumatoid cachexia: a clinical perspective Rheumatology, August 1, 2008; 47(8): 1124 - 1131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Sorror, S. Giralt, B. M. Sandmaier, M. De Lima, M. Shahjahan, D. G. Maloney, H. J. Deeg, F. R. Appelbaum, B. Storer, and R. Storb Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences Blood, December 15, 2007; 110(13): 4606 - 4613. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Sorror, B. M. Sandmaier, B. E. Storer, M. B. Maris, F. Baron, D. G. Maloney, B. L. Scott, H. J. Deeg, F. R. Appelbaum, and R. Storb Comorbidity and Disease Status Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation J. Clin. Oncol., September 20, 2007; 25(27): 4246 - 4254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Kinder, A. B. Hassell, J. Brand, A. Brownfield, M. Grove, and M. F. Shadforth The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions Rheumatology, January 1, 2005; 44(1): 61 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Rall and R. Roubenoff Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions Rheumatology, October 1, 2004; 43(10): 1219 - 1223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. A. Morrison, K. R. Rai, B. L. Peterson, J. E. Kolitz, L. Elias, F. R. Appelbaum, J. D. Hines, L. Shepherd, R. A. Larson, and C. A. Schiffer Therapy-Related Myeloid Leukemias Are Observed in Patients With Chronic Lymphocytic Leukemia After Treatment With Fludarabine and Chlorambucil: Results of an Intergroup Study, Cancer and Leukemia Group B 9011 J. Clin. Oncol., September 15, 2002; 20(18): 3878 - 3884. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Edelson, A. N. A. Tosteson, and P. Sax Cost-effectiveness of Misoprostol for Prophylaxis Against Nonsteroidal Anti-inflammatory Drug--Induced Gastrointestinal Tract Bleeding JAMA, July 4, 1990; 264(1): 41 - 47. [Abstract] [PDF]
|
|